Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297381 | 0.72 | — | — | |
| SCHEMBL4559906 | 0.72 | — | — | |
| SCHEMBL28835995 | 0.70 | — | — | |
| SCHEMBL16454693 | 0.69 | — | — | |
| SCHEMBL25479758 | 0.68 | TP53 (0.36) | ALDH1A1HSD17B10 | |
| SCHEMBL28835987 | 0.67 | — | — | |
| SCHEMBL6677934 | 0.65 | — | — | |
| SCHEMBL20428181 | 0.65 | KDM4E (0.30) | — | |
| SCHEMBL28930070 | 0.65 | SHBG (0.46) | ALDH1A1 | |
| SCHEMBL83493 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472244-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| WO-2003045944-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | ALDH1A1 564/4885AR 777/4885TSHR 3531/4885 |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | ALDH1A1 564/4885AR 777/4885TSHR 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.